Search results
Pfizer sees $10 billion-$15 billion in potential revenue from mRNA vaccines by 2030
Reuters via Yahoo News· 1 year agoIn November, Pfizer had raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to...
Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent...
Benzinga via Yahoo Finance· 1 year agoAt Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio...
Pfizer sees steep 2023 fall in COVID sales, aims to bolster pipeline
Reuters via Yahoo News· 1 year agoPfizer Inc on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and...
Pfizer rides Paxlovid sales to better-than-expected quarter
Associated Press via Yahoo News· 1 year agoPfizer’s COVID-19 treatment helped the pharmaceutical giant balance tumbling international sales for...
3 Reasons Why It’s a Good Time to Buy PFE Stock
InvestorPlace via Yahoo Finance· 1 year agoTo say the Covid-19 vaccination wave in 2021 moved the needle for Pfizer (NYSE:PFE) stock is an understatement. Revenue nearly doubled thanks to its vaccine candidate (Comirnaty), which the ...
100 Billion Reasons to Like This Dominant Healthcare Stock
Motley Fool· 2 years agoPicking companies with size and scale on their side tends to be a smart move for investors. This is...
2 Top Biotech Stocks to Buy Right Now
Motley Fool· 1 year agoPharmaceutical companies can be great long-term investments. Because of the major industry risk that comes with patent expirations, investors need to be...
